QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Q32 Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.79+0.27 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $158.47M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Share price
+$4.62 (+145.7%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Q32 Bio Inc. reported revenue of $53.74M for fiscal 2025. Free cash flow was -$33.54M.
Revenue
$53.74M
FY2025
Operating income
$21.46M
TTM Q2 2026
Free cash flow
-$33.54M
FY2025
EPS, diluted
$2.42
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $158.47M
- P/E ratio
- 3.2
- Price to sales
- 2.95
- Price to book
- 1.50
- Dividend yield
- –
- Free cash flow yield
- -21.17%
Fundamentals
- Revenue
- $53.74M
- Net income
- $33.79M
- EPS, diluted
- $2.42
- Free cash flow
- -$33.54M
- Book value per share
- $5.21
- Diluted shares
- 20M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
$21.46M
Net income
$33.79M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months